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REVIEW

Trypanothione Reductase: A Viable Chemotherapeutic
Target for Antitrypanosomal and Antileishmanial Drug Design
M. Omar F. Khan
College of Pharmacy, Southwestern Oklahoma State University, 100 Campus Drive, Weatherford,
OK 73096, U.S.A.
Abstract: Trypanosomiasis and leishmaniasis are two debilitating disease groups caused by parasites of Trypanosoma and
Leishmania spp. and affecting millions of people worldwide. A brief outline of the potential targets for rational drug design
against these diseases are presented, with an emphasis placed on the enzyme trypanothione reductase. Trypanothione reductase was identified as unique to parasites and proposed to be an effective target against trypanosomiasis and leishmaniasis. The biochemical basis of selecting this enzyme as a target, with reference to the simile and contrast to human analogous
enzyme glutathione reductase, and the structural aspects of its active site are presented. The process of designing selective
inhibitors for the enzyme trypanothione reductase has been discussed. An overview of the different chemical classes of
inhibitors of trypanothione reductase with their inhibitory activities against the parasites and their prospects as future chemotherapeutic agents are briefly revealed.
Key words: Trypanothione, glutathione, Chagas disease, sleeping sickness, rational drug design

Introduction

Trypanosomiasis and leishmaniasis are among the major debilitating and devastating tropical diseases
that are targets for the World Health Organization’s special program Research and Training in Tropical
Diseases (TDR) (Hyde, 1990) and most recently the Drugs for Neglected Diseases initiative (DNDi,
www.dndi.org). These diseases are caused by the parasites of the genus Trypanosoma and Leishmania.
The present review focuses on the major human diseases caused by trypanosomal and leishmanial
infections and the potential targets for designing chemotherapeutic agents against these diseases with
special emphasis on trypanothione reductase. Table 1 gives an outline of the major human trypanosomiasis and leishmaniasis with their global annual disease burdens (as of 1999) in terms of disability
adjusted life years (DALY).
Table 1.The major trypanosomiasis and leishmaniasis, causative agents, their global burdens in terms
of Disability Adjusted Life Years (DALY) and current treatments.
Disease

Causative agents

DALY*
(million/year)

Current Treatments

African
trypanosomiasis
or sleeping
sickness
American
trypanosomiasis
or Chagas disease
Visceral
leishmaniasis
or kalazar
Dermal
leishmaniasis
or tropical sore

Trypanosoma brucei
gambiense and
T. b. rhodesiense

1.2

Suramine, pentamidine,
DFMO, tryparsamide

T. cruzi

0.6

Benznidazole, nifurtimox

Leishmania donovani

1.7

Pentostam, glucantime,

L. major, L. tropica,
L. braziliensis, L. mexicana

aminosidine

*Taken from World Health Report 1999, publ. World Health Organization Geneva (1999).
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Suramine (1) and pentamidine (2) are useful
drugs for treating Human African Trypanosomiasis (HAT) during early infection, but being
highly charged, cannot cross the blood brain
barrier and are of no use for late stage infection
with involvement of central nervous system
(CNS) with either Trypanosoma brucei gambiense
or T. b. rhodesiense. Melarsoprol (3), a trivalent
arsenical, or tryparsamide (4) is then used.
Difluoromethylornithine (DFMO, 5) is effective
in treatment of HAT, but is not very effective
against rhodesiense sleeping sickness where large
doses must be used, resulting in significant
side-effects, including bone marrow suppression
(Meshnick, 1984; Neva and Brown, 1994).
Nifurtimox (6), a nitrofuran derivative, is the best
drug currently available for treating Chagas
disease but is still considered investigational. It
is thought to kill trypanosomes selectively
through futile cycling by the formation of
hydrogen peroxide and toxic oxygen species
(Docampo and Stoppani, 1979; Le Trant et al.
1983; Docampo and Moreno, 1984a and b, 1986;
Neva and Brown, 1994). Benznidazole (7) is of
equivalent effectiveness and is used in South
America in the acute stage. Both drugs must be
given for several months and are associated with
severe side effects (Neva and Brown, 1994).
Recently, the present and future prospects of
chemotherapy of HAT, in addition to the possible
mode of action and the mechanism of resistance
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of the current chemotherapeutic agents have been
reviewed (Fairlamb, 2003a).
Pentavalent antimonials e.g. pentostam (8) is
the recommended treatment for visceral leishmaniasis but are toxic and developed resistance
(Croft, 1988; Grogl et al. 1992). Relapse of disease
or only partial response is more common in Kenya,
the Sudan, and India than in Mediterranean or Latin
American kala azar, where a second or longer
course of treatment is often needed.
Overall, the demand for chemotherapeutic
agents for the treatment of Chagas disease,
sleeping sickness and kala azar is desperate.
Those needing treatment are mainly in impoverished rural and urban communities with poor
housing and limited access to medical attention,
and in countries where basic healthcare infrastructures have yet to be developed. Approved
chemotherapies that are available were developed
in the first half of the last century (suramine,
pentamidine, arsenicals and antimonials); some
would fail today’s more stringent standards for
drug safety. Given the initial success of a largely
empirical approach, progress in drug development
in recent years has been poor and, undoubtedly
there is great need for new less toxic treatments
for human diseases by parasitic trypanosomes and
leishmanias. In view of the economies of the Third
World countries suffering most from these
diseases, such drugs will have to be cheap and
simple to administer.

N
SO2

CH2OH

H2 N

2

2

O
HO As O-Na+

CHF2
COOH
NH2

H 2N
4

NH2+
NH2

O(CH2)5O

5
NHCH2CONH2

CH2CONHCH2
N
NO2
7
N

COOH
HO
HO

COOH
OH

O
O
Sb Sb
O
O
O
O
O
OH
8

OH
OH

Figure 1. Structures of the currently available drugs for the treatment of trypanosomiasis and leishmaniasis.
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Potential Chemotherapeutic
Targets for Trypanosomiasis
and Leishmaniasis

In this genomic, proteomic, and bioinformatics
era of target identification, scores of potential
targets for antitrypanosomal and antileishmanial
chemotherapy will be emerging. In the pregenomic era, basic research in molecular biology
and multidimensional research initiatives has
identified some biological features associated
with the development of trypanosomiasis that
have been well documented and studied extensively. Ergosterol biosynthesis, parasite specific
proteases and reductases, purine salvage and
phospholipid biosynthesis (for review see Urbina,
2003) could be turned into targets, provided that
the following two requirements can be met: (a)
the target must be essential for the survival of the
parasites, and (b) the target must be such that a
counterpart in the mammalian host either does
not exist or is sufficiently different to allow
selective inhibition (Wang, 1995). The technological advancements related to post-target
selection are also important criteria. Because the
target must be suitable for study at the molecular
level that include most importantly the high
throughput screening for which convenient, cheap
and sensitive assay methods are highly desirable.

Glycolytic pathway

As trypanosomal cells are completely energetically dependent on glycolysis it might be used to
develop new trypanocidal drugs (Michels, 1988).
Compertmentation of glycolytic enzymes is
generally assumed to result in an enhancement of
the rate of glycolysis in bloodstream trypanosomes, approximately 50-times higher than that
in mammalian cells (Brohn and Clarkson, 1980).
This appears to be necessary to compensate for
poor yields of energy. Trypanosomes need to
replicate every 6 to 8 h in mammalian blood and
Varian surface glycoproteins (VSGs) must be
replaced frequently to evade a host immune
response (Donelson and Rice-Ficht, 1985). Thus
it has been suggested that inhibition of any one
of the glycolytic enzymes inside the glycosomes
may block glycolytic activity and kill bloodstream
trypanosomes (Clarkson and Brohn, 1976;
Michels, 1988). The three dimensional (3D)
structure of T. brucei glycosomal triosephosphate
isomerase (TIM), determined at 2.4 Å resolution,
Drug Target Insights 2007: 2

was found to be very similar to that of mammalian
TIM (Wierenga et al. 1987). The 3D structure of
glycosomal glyceraldehyde-3-phosphate dehydrogenase (GADPH) (Vellieux et al. 1993) could
provide opportunities for designing selective
inhibitors as it differs from the mammalian
homolog (Verlinde et al. 1994; Wang, 1995).
Bloodstream T. b. brucei imports glucose by
facilitated diffusion and the uptake of glucose
apparently represents the rate-limiting step in
glycolysis. The genes encoding trypanosomal
glucose transporters are tandemly arranged in a
multigene family consisting of two homologous
groups, trypanosome hexos transporter (THT)1
and THT2. THT1-encoded glucose transporters,
preferentially expressed in a bloodstream form,
have a moderate sensitivity to cytochalasin B and
recognize D-fructose as substrate, thereby distinguishing them from the human erythrocyte
glucose transporter. They are potential targets for
antitrypanosomal chemotherapy (for review, see
Wang, 1995).

DNA topoisomerases

Many of the established antiprotozoal agents are
known to bind to DNA. There are two potential
sites for DNA binding in members of the kinetoplastida: nuclear and kinetoplast DNA. In
general, DNA binding agents would be expected
to be active against protozoa, but toxicity is a
major factor. It was assumed that binding to DNA
leads directly to inhibition of DNA-dependent
processes, but it is now generally accepted that
intercalating agents induce topoisomerase II –
mediated strand breaks in DNA (Brown, 1987).
Trypanosomal topoisomerase II inhibitors affect
both nuclear and mitochondrial DNA and may
prove to be effective and safe antitrypanosomal
drugs (Shapiro, 1993) as they differ structurally
from mammalian topoisomerase II (Shapiro and
Showalter, 1994). DNA topoisomerase I could
also serve as an intracellular target, as its inhibition can cause DNA-cleavage and ultimate death
of trypanosomes (Bodley et al. 1995).

Ergosterol biosynthesis

Ergosterol biosynthesis is a novel metabolic
pathway essential for parasitic survival lacking a
counterpart in the host. Several enzymes of this
pathway, e.g. squalene synthase, fernesylpyrophosphate synthase are capable of depleting
131

Khan

As shown in Figure 2, ornithine decarboxylase
(ODC), S-adenosyl-L-methionine decarboxylase
(SAMDC) and spermidine synthetase in
trypanosomes serve crucial functions (Fairlamb
and Bowman, 1980) and may be potential targets
for antitrypanosomal chemotherapy. Little is
known about trypanosomal SAMDC except that it
did not cross-react with human SAMDC antiserum
(Tekwani et al. 1992). Detailed comparison of
mammalian and trypanosomal SAMDCs have not
yet been done nor have crystal structure and amino
acid sequence been determined, steps important
for designing drugs active against this enzyme.
Trypanothione is a conjugate of glutathione
and the polyamine spermidine. This polyamine
component of the structure of trypanothione
disulfide (T[S]2) rationalized the actions of several
antitrypanosomal and antileishmanial drugs. For
example, DFMO (5), the first new drug licensed
to treat HAT for over 50 years, inhibits ODC,
which catalyzes the initial step in polyamine
biosynthesis (Fig. 2), decreasing the trypanothione pool. The origin of the trypanocidal effect
of DFMO has not been established (Fairlamb and
Cerami, 1992).

endogenous sterols, and therefore represent viable
chemotherapeutic targets (for review, see Linares
et al. 2006).

Purine salvage pathway

Some striking differences between parasites and
their mammalian host are apparent in purine
metabolism. Unlike their mammalian host, most
parasites lack the de novo purine biosynthetic
mechanisms and rely on salvage pathways to meet
their purine needs. There are sufficient distinctions
between enzymes of the purine salvage pathway
in host and parasite that can be exploited to design
specific inhibitors or “subversive substrates” for
the parasitic enzymes. Furthermore, the specificities of purine transport, the first step in purine
salvage, differ significantly between parasites and
their mammalian host to allow selective inhibitor
design (for review see El Kouni, 2003).

Polyamine biosynthesis

The ability to synthesize polyamines (Fig. 2) is
vitally important for the proliferation of bloodstream
HAT in an environment deficient in polyamines.
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Figure 2. Metabolism and function of trypanothione, showing possible sites of action of trypanocidal compounds. The insert above illustrates
the futile redox cycling by nitro compounds (RNO2) to form hydrogen peroxide (H2O2) and hydroxyl radicals (OH●). Abbreviations: BSO,
buthionine sulfoximine; DFMO, difluoromethylornithine; R-As=O, melarsen oxide; Mel T, melarsen trypanothione adduct; PUT, putrescine;
SPD, spermidine; dSAM, decarboxylated S-adenosylmethionine; MTA, methylthioadenosine (modified from Krauth-Siegel et al. 1987).
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Trypanothione reductase (TR) and the synthetic
enzyme of trypanothione metabolism found in
trypanosomatids exemplify unique features of the
organisms. As shown in Figure 2, trypanothione
synthesis proceeds from glutathione; the similar
redox potentials allow for nonenzymatic thiol-disulfide exchange reactions to occur (Fairlamb and
Cerami, 1992). Considerable advances have been
made in characterization and inhibitor design against
TR. The key enzyme of the two-step trypanothione
biosynthesis, glutathionyl spermidine synthetase,
was isolated, partially sequenced and kinetically
analyzed (Koenig et al. 1997). The utilization of
trypanothione for the reduction of hydroperoxides
has remained a matter of debate. A trypanothione
peroxide activity, presumed to substitute for the
glutathione peroxide activity typical of host metabolism (Flohé, 1989), was observed in crude extracts
of various trypanosomatids (Henderson et al.
1987a). Consistent failures to isolate putative
trypanothione peroxidases, and substantial spontaneous reaction rates between trypanothione and
hydrogen peroxide, led to the conclusion that
trypanothione-dependent peroxide metabolism may
represent a non-enzymatic event (Carnieri et al.
1993). Recent discoveries have demonstrated
(Nogoceke et al. 1997) that the reduction of peroxides by trypanothione is an enzymatic process, but
in contrast to previous expectations, is catalyzed by
two distinct proteins in concert (Flohé, 1998).
Lipoamide dehydrogenase (LipDH) is another
flavoprotein dependent enzyme, which has been
discussed as a target molecule for antitrypanosomal therapy. In T. cruzi, an organism highly
susceptible to oxidative stress, LipDH participates
in the redox cycling of nifurtimox, one of the most
effective anti-Chagas agents (Krauth-Siegel and
Schöneck, 1995).
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Regeneration of protective GSH from GSSG is
catalyzed by GR. In trypanosomes and leishmanias
an analogous system has evolved (Fairlamb and
Cerami, 1992) insofar as the disulfide (T[SH]2) differs
from GSSG by the presence of a spermidine cross-link
between the two glycyl carboxyl groups (compare
GSSG and T[S]2). The enzyme TR reduces T[S]2 to
dithiol T[SH]2 in a manner analogous to GR (Fig. 3).
With this discovery of a fundamental metabolic difference, TR was proposed and amplified further as a
target for the rational design of antitrypanosomal and
antileishmanial drugs (Fairlamb et al. 1985; Shames
et al. 1986; Benson et al. 1992; Hunter et al. 1992;
Schirmer et al. 1995).
Unlike human hosts, trypanosomes contain TR
instead of analogous enzyme GR to process their
cognate substrates trypanothione and glutathione,

Trypanothione Reductase
as a Chemotherapeutic Target

In the pre-genomic era investigation of mode of
action of arsenical drugs and glutathione biosynthesis inhibitor, buthionine sulfoximine (BSO),
gave rise to the discovery of trypanothione, unique
to trypanosomes and absent from the mammalian
cells (Fairlamb et al. 1985). In mammals, potential
redox damage meets the glutathione (GSH)-based
system as a first defense, during the course of
which glutathione disulfide (GSSG) is formed
(Equation 1).

H3N
CO2-

+

(1)

GSSG

GSH

HOST
GSSG

NADPH

REACTIVE
OXYGEN
SPECIES

GR
NADP+

T[S]2

GSH

NADPH
TR

T[SH]2

NADP+

PARASITE
Figure 3. Outline of glutathione and trypanothione based redox
defences.
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respectively. Parasite TR does not process GSSG and
host GR does not reduce T[S]2 (Shames et al. 1986;
Krauth-Siegel et al. 1987). Selective inhibitor design
is probable, due to the mutually exclusive recognition
and rejection of cognate substrates between host and
parasite (Shames et al. 1986; Krauth-Siegel et al.
1987; Schirmer et al. 1995). Efficient selective
blockade of TR would be expected to compromise
the redox defences of the parasites, increasing their
sensitivity to redox-damage based drugs, e.g. nifurtimox. A TR inhibitor might be expected to be drug
in its own right or for co-administration with a redoxactive drug e.g. nifurtimox. The later case may even
provide synergy, allowing use of lowered doses of
the redox drug (Chan et al. 1998).
TR is a member of the large well-characterized
protein family of FAD-dependent NADPH oxidoreductases (reviewed in Williams, 1992) and share
close structural and mechanistic similarities with
that of GR (summarized in Table 2). It is a dimeric
protein of monomer molecular mass 52kDa,
providing FAD-binding, NADPH-binding, central
and interface domains. There are two identical
active sites, formed by residues of the FAD,
NADPH, and central domains of one monomer and
the interface domain of the other (Fig. 4).

Validating suitability of trypanothione
reductase as a target

To validate TR as a viable target for rational drug
design, inhibition of TR in vitro should correlate
with an observable effect in vivo. This is a difficult
test to satisfy unambiguously; biochemical and
molecular biological attempts had been made to
probe TR as a reasonable drug target. In absolute
terms, disruption or deletion of the TR genes in
parasites should be lethal. Over-expression of TR
in transfected L. donovani promastigotes was not
found to alter the sensitivity to hydrogen peroxide
indicating that the regeneration of T[SH]2 from its
disulfide after oxidative challenge is not the ratedetermining feature of the defense system (Kelly et
al. 1993). Over-expression of TR in T. cruzi led to
gene rearrangements when antisense modulation of
TR expression was attempted (Tovar and Fairlamb,
1996). Disruption of two of the TR alleles of Leishmania failed to produce a null mutant, and actually
produced a third copy of TR gene by genomic rearrangement to a larger chromosome (Dumas et al.
1997). Down-regulation of TR using a trans-dominant mutation strategy demonstrated that even with
134

only 15% residual TR activity, promastigote growth
is still supported in culture (Tovar et al. 1998a). It
was proposed that any rationally designed inhibitor
of TR must attain >85% inhibition for activity as an
antileishmanial species, but it was pointed out that
such cells are more sensitive to oxidative insult, such
as the oxidative burst of macrophages, and that
clinically usable TR inhibitors may need to be as
effective in vivo (Tovar et al. 1998a). Later it had
been demonstrated that TR absence is incompatible
with parasite survival and validated TR as a bonafide
drug target. As it was not possible to obtain viable
Leishmania devoid of TR catalytic activity, specific
inhibitors of this enzyme are likely to be useful
antileishmanial agents for chemotherapeutic use
(Tovar et al. 1998b).
Sequence alignment of TRs and human GRs
(hGRs) showed that relative to TR hGR has an Nterminal extension, a C-terminal truncation and
several deletion and insertions throughout the
sequence. The most striking regions of homology
are 14-residue sequence containing the redox-active
cysteine residues and the 10-residue sequence
containing the active site histidine. Although the
disulfide-binding site in TR in general rather closely
resembles that for GSSG in GR, they have over
1000-fold selectivity for their cognate substrates,
the molecular basis for which involves size, charge
and hydrophobicity of their active sites. TR binding
site is much wider in the outer region (~22 Å × 20
Å × 28 Å) due to different orientations of two helices

Trypanothione

Interface

FAD
NADPH

Figure 4. Structure of trypanothione reductase with FAD, NADPH
and trypanothione bound (modified from Bond et al. 1999).
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in the FAD domains (Kuriyan et al. 1991). The TR
active site is more hydrophobic and has an overall
negative charge to attract its positively charged and
more hydrophobic polyamine containing cognate
substrate trypanothione and repel the negatively
charged smaller host substrate glutathione.
Conversely, the GR active site is smaller and positively charged, repelling the larger and positively
charged trypanothione. The X-ray crystal structures
of TRs from Crithedia fasciculata (Kuriyan et al.
1991; Hunter et al. 1992), and T. cruzi have been
solved (Lantwin et al. 1994; Zhang et al. 1996). The
crystal structure of TR in complex with trypanothione was solved (Bond et al. 1999) as was the
crystal structure of TR complexed with the alternative substrate glutathionyl spermidine (Bailey et al.
1993) and with the weak, but selective, inhibitor
mepacrine (Jacoby et al. 1996). As already pointed
out, a convenient screening technology is highly
desirable for a suitable substrate to expedite the drug
discovery process. To this end, a convenient colorimetric plate assay suitable for automated highthroughput screening has been developed by
Hamilton et al. (2003).
One disadvantage of selecting TR as a drug
target for the development of broad-spectrum
antiparasitics is that intracellular trypanothione
concentrations vary from 0.3 mM in African
trypanosomes to ~3.0 mM in Leishmania spp.,
>99% of which is in the reduced form. As soon as
TR is inhibited, T[S]2 will start to accumulate due
to continuing intracellular oxidant process. It is not
currently known what T[S]2/T[SH]2 ratio is lethal
to the parasite. It has been suggested that the design
of competitive inhibitors with Ki-values in nM
range will be required, and the design of irreversible
inhibitors may represent a better strategy for drug
development (Fairlamb, 2003b).
The following section will focus on recent discoveries of different classes of TR inhibitors, which
demonstrated antiparasitic activity and promise of
development of newer chemotherapeutic agents.

Rational drug design based on
trypanothione reductase as a target

The homology modeling of TR (Benson et al. 1992)
with that of hGR shed light on the structural aspects
of the enzyme also in addition to its substratebinding mode from a theoretical perspective. Studies
with various alternative peptide substrates demonstrated that the spermidine moiety of trypanothione
136

could be conveniently replaced with N,N-dimethylaminopropylamide (dmapa) without loss of
substrate activity. Subsequently, a series of alternative γ-glutamyl-modified trypanothione substrates
were synthesized. The discovery that a benzyloxycarbonyl (Z) group represented a suitable replacement resulted in (Z.Cys.Gly.dmapa)2 as a convenient
alternative assay substrate in which the Z group
occupies a hydrophobic pocket near Phe396’ of TR
(Henderson et al. 1987b; El-Waer et al. 1991, 1993a
and b; Marsh and Bradley, 1997). This pocket was
since named the Z-site, approximately enclosed by
Phe396’, Pro398’ and Leu399’. This initial advancement in structural aspects of TR active site prompted
the discovery of peptide inhibitors (Garforth et al.
1994; McKie et al. 2001; Chan et al. 2002). The first
rationally designed non-peptide inhibitors are represented by the tricyclic ring structures that are
competitive versus trypanothione (Benson et al.
1992). Progress has been made in discovering large
classes of inhibitors of TR over recent years, which
are also found to be lethal to parasites in vitro.

The tricyclic compounds
and congeners

Molecular modeling approaches were useful in
identifying tricyclic antidepressants including
phenothiazines and related structures (e.g. 9, 10)
and mepacrine (11) (Fig. 5) as competitive
inhibitors of TR but not GR (Benson et al. 1992;
Jacoby et al. 1996; Chan et al. 1998). The tricyclic
moiety of these compounds were shown to lodge
against the hydrophobic wall of TR active site
formed by Trp21 and Met113, with the aminopropyl side chain pointing towards the Glu466’
and Glu467’ residues. The synthesis and biological evaluation of a series of dibenzazepine
analogs (Garforth et al. 1997), N-acylpromazines,
2-substituted phenothiazines, and trisubstituted
promazines failed to show any improvements over
the parent leads (Chan et al. 1998).
The antimalarial drug mepacrine (11), an acridine derivative, is also a competitive inhibitor of
TR. The acridine ring also aligns to the hydrophobic wall of TR formed by Trp21 and Met113,
but the alkylamino side chain point towards Glu18,
unlike the tricyclics described above (Bonse et al.
1999). Sulfonamides and urea derivatives of
mepacrine with varying methylene spacer lengths
(e.g. 12, 13) were found to be superior inhibitors
of TR relative to mepacrine with the best inhibitors
Drug Target Insights 2007: 2
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Figure 5. Structures and activities of tricyclic inhibitors of trypanothione reductase.

being 40-fold more potent (Chibale et al. 2001). A
series of synthetic 9,9-dimethylxanthene derivatives (e.g. 14) were shown to be competitive
inhibitors of TR which are comparable to known
tricyclic inhibitors of TR (Chibale et al. 2003).
It is important to note that as required in principle for an ideal drug target, inhibition of TR in
vitro should also correlate with antiparasitic
activity in vitro against T. brucei, T. cruzi and
L. donovani. However, no strong correlation
between TR-inhibitory activity and in vitro antiparasitic activity was observed indicative of unfavorable pharmacokinetic profiles.

2-Aminodiphenylsulfides
and its congeners

Modification of the central ring of the phenothiazines furnished the 2-aminodiphenylsulfides,
termed ‘open chain chlorpromazines’. Using a
microplate assay to screen TR inhibitors, this group
of compounds was discovered to be potent competitive inhibitors (Fig. 6). Compound 15 was the best
inhibitor in the preliminary series (FernandezGomez et al. 1995). Based on these results and
molecular modeling studies, a series of bis
(2-aminodiphenylsulfides) were synthesized and
compound 16 was shown to be the most potent in
this series (Girault et al. 1997). Further improvement was evident with a newer generation of
Drug Target Insights 2007: 2

bis(2-aminodiphenylsulfides) (e.g. 17) corresponding to attachment of an additional hydrophobic side to an analog of compound 16. The
large volume of the TR active site justified the
introduction of an additional hydrophobic group
to the end of the side chain (Girault et al. 2001).
All the compounds demonstrated antiparasitic
activity in vitro at low micromolar ranges.
However, no correlations between TR inhibition
and in vitro antiparasitic activity were apparent.

Quaternary alkylammonium
compounds

The quaternization of tertiary alkylamine ω-nitrogen
atom of chlorpromazine by substituted benzyl and
other aromatic or heterocyclic groups resulted the
discovery of quaternary alkylammonium phenothiazines as a new class of linear competitive
inhibitors of TR (Fig. 7) (Khan et al. 2000). The
permanent positive charge on the distal nitrogen
atom of the tricyclic’s side chain contributed to
binding was estimated as ≥5.6 kcal.mol-1 by
comparison with the analog with cationic nitrogen
atom of the quaternary (18) replaced by an ether
oxygen atom (19). The major contribution to
improving K i value and inhibition strength
was accomplished by incorporating the hydrophobic N-benzyl substituents. The best inhibitor
identified was compound 19, containing a 3,
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Figure 6. Structures of 2-aminodiphenylsulfides with their anti-TR activities.

4-dichlorobenzyl substituent (~2 orders of
magnitude >chlorpromazine).
Detailed molecular modeling studies helped to
establish docking orientations and energies by
revealing involvement of: (i) the major hydrophobic pocket (Trp21, Met113, Tyr110), (ii) the
“Z”-site (Phe396’, Pro398’, Leu399’) and (iii) the
ionic interactions possible for the quaternary
cationic nitrogen with nearby side chains of

Cl

N
ClH3C N+
H3C

S

S

S
Cl

Glu466’ and Glu467’ (Fig. 8) (Austin et al. 1999,
Khan et al. 2000). This “three point attachment”,
a concept initially designed by Ogston (1948) to
explain chiral specificity of enzymes, has allowed
on average a 30-fold improvement of Ki values
against TR (Khan et al. 2000).
Similarly, the quaternization of the side chain
tertiary nitrogen atom of the ‘open chain chlorpromazines’ also showed improvements in inhibition up to

Cl

18, Ki = 0.12 M
(Khan et al. 2000)

O
Cl

Cl
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Figure 7. Structures of quaternary alkylammonium compounds with their anti-TR activities.
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Figure 9. Structures and trypanothione reductase inhibitory activities
of polyamine derivatives.

Figure 8. Compound 18 docked into active site of TR to show major
interactions (taken from Austin et al. 1999).

40-fold. The most potent compound synthesized from
this series was the 3, 4-dichlorobenzyl analog (20)
(Parveen et al. 2005). All analogs demonstrated strong
inhibition, some in lower nM ranges, against the blood
stream form of T. brucei. Antiparasitic activity was
not solely determined by the inhibition strength against
TR; a strong contribution from hydrophobicity was
also observed. Although active against L. donovani,
none showed major improvement in this activity relative to their parent compounds. Some of the analogs
also showed improved inhibition against the amastigote stage of T. cruzi with ED50 values <1 µM (Khan
et al. 2000; Parveen et al. 2005).

Solid phase synthesis approaches allowed for the
expedient synthesis of polyamine-based focused
libraries as potential TR inhibitors. Several potent
inhibitors were identified with low nM activity
(Orain and Bradley, 2001; De Luca et al. 2003).
Most of these compounds also displayed potent
in vitro antiparasitic activity against T. brucei with
ED50 values <1 µM (O’Sullivan et al. 1997; Li et al.
2001; Bi et al. 2006). These preliminary antiparasitic
activity in vitro are suggestive of their TR involvement although well correlation between TR-inhibition and trypanocidal activity were not evident.

Bisbenzylisoquinoline alkaloids

The bisbenzylisoquinoline alkaloids were also
shown to be potent inhibitors of TR and trypanocidal agents (Fournet et al. 1998, 2000). Six of the
alkaloids evaluated displayed potent trypanocidal
activity in vitro against T. cruzi with ED50 values
<100 µM. The best TR inhibitor, cepharanthine

Polyamine derivatives

As shown in Scheme 1, the natural disulfide
substrate of TR, T[S]2, differs from the analogous
host’s GSSG only by the presence of a spermidine
(a polyamine) cross-link between the two glycyl
carboxyl groups. This discrimination between
parasite and host substrate served as a criterion for
developing polyamine derivatives as selective
inhibitors of TR (O’Sullivan and Zhau, 1995;
O’Sullivan et al. 1996, 1997; Baillet et al. 1996; Li
et al. 2001; Bi et al. 2006). This approach led to the
discovery of series of potent selective competitive
inhibitors of TR, several selected compounds are
included in Figure 9 (compounds 21, 22).
Drug Target Insights 2007: 2
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(23), had an I50 value of 15 µM which is the same
order of magnitude as its ED50 against the parasites,
suggesting that inhibition of TR could be the
mechanism of their trypanocidal activities.

Natural products

Natural products may be considered as “nature’s
medicine chest” and have served as a potential
source of TR-inhibitors. The natural antihypertensive agent, kukoamine A (24), a bis (trihydrocinnamoyl) spermidine derivative, first isolated
from Lycium chinense, was identified as a mixed
type of inhibitor of TR (Ponasik et al. 1995).
Virtual screening of a large number of chemical
databases, using the TR active site as the targeted
template, identified the natural spermine-based
macrocyclic alkaloid lunarin (25) (originally isolated
from Lunaria biennis) as TR-inhibitor, which was
shown to inhibit the enzyme in a time-dependent
manner (Bond et al. 1999). Further investigation
with synthetic derivatives confirmed the importance
of the unique structure of the tricyclic core as a motif
for inhibitor design and revealed that the non-natural
enantiomer may be a more suitable scaffold upon
which thiophilic groups may be presented (Hamilton
et al. 2006). Ajoen (26) a garlic derived natural
sulfur-containing compound was established as an
irreversible inhibitor and subversive substrate of
both TR and GR (Gallwitz et al. 1999). Most of
these natural products also inhibited the parasites in
vitro in one way or another.

Irreversible inhibitors

The anticancer nitrosourea drug carmustin was the
first ligand to display irreversible inactivation of
TR, but non-specifically as also inactivated hGR,

by carbamoylating an active site cystinyl residue,
which becomes accessible after being reduced by
NADPH (Schirmer et al. 1995). Ajoen (26), as
previously mentioned as a natural product inhibitor,
is an irreversible non-specific inhibitor of TR
(Gallwitz et al. 1999). The first rationally designed
and selective irreversible inhibitors of TR include
the Pt-complexes of terpyridine derivatives (e.g.
27), which inhibit the reduced TR, presumably
through occupying the Cys52 by replacing its
fourth pyridine ligand (Bonse et al. 2000).
Coupling the irreversible ligand (terpyridine)Pt2+
complex with an 9-aminoacridine derivative (a
competitive inhibitor) furnished mixed-type
inhibitors (e.g. 28) (Inhoff et al. 2002). An important advancement was made with the quinacrine
mustard (29), which was shown to selectively and
irreversibly inactivate TR in a time-dependent
manner with a stoichiometry of two inhibitors
bound per monomer. The rate of inactivation was
dependent upon the oxidative states of TR, with
NADPH-reduced TR form being inactivated faster.
The structure of TR-quinacrine mustard-adduct
solved to 2.7Å revealed that two molecules of
ligand are bound in the trypanothione binding site
of TR. Each acridine moiety interacts through πstacking, while only one of the acridine groups
interacts with a trypanothione residue in a similar
fashion (Saravanamuthu et al. 2004).
Recently, several Mannic bases (e.g. 30) were
shown by Lee et al. (2005) to be irreversible
inhibitors of TR. HPLC, NMR and MS analyses
were performed to delineate their mechanism of
action and found that divinyl ketone are the key
intermediates to irreversibly inhibit TR. ESI- and
MALDI-TOF-MS of TR, modified by Mannic base
or corresponding divinyl ketone, demonstrated
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Figure 11. The natural product inhibitors of trypanothione reductase.
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reduce these futile, superoxide ion producing
substrates in a single electron step (NADPH +
2RNO2 → 2RNO2•‾ + 2H+; 2RNO2•‾ + O2 →
2RNO2 + O2•‾), a process by which NADPH and
O2 are wasted and T[SH]2 is inhibited/oxidized by
scores of newly formed superoxide ions causing a
reduction in thiol/disulfide titer and thus producing
oxidative stress (Henderson et al. 1988; Schirmer
et al. 1995). This group of compounds, known as
‘subversive substrates’ or ‘turncoat inhibitors’, are
best represented by nitrofurans or quinones,
chemically modified to take into account the
substrate specificity for TR over GR (Cenas et al.
1994a and b). Thus, chinifur (31), a nitrofuran
derivative with a positively charged side chain,
was discovered as a selective inhibitor and subversive substrate of TR (Cenas et al. 1994a). Recently,
the anti-TR activities of a series of nitrofuran and
nitroimidazole derivatives were studied to examine
the mechanism of action of different types of

specific alkylation of Cys52 in a manner as shown
in Figure 13 (Lee et al. 2005).
Sixteen novel Pd-complexes of the bioactive
nitrofuryl thiosemicarbazones were synthesized and
tested for their in vitro activity (Otero et al. 2006).
Most complexes showed higher in vitro trypanocidal
activity against T. cruzi than the standard drug nifurtimox. Overall, the activities of Pd complexes ≥their
parent compounds. It has been suggested that main
trypanocidal mechanism was the production of
oxidative stress as a result of their bioreduction with
the reductive enzymes, although strong DNA-adduct
formation was also evident (Otero et al. 2006).

Subversive substrates
of trypanothione reductase

Nifurtimox (6) and related compounds exert their
parasiticidal activity through acting as futile, superoxide ion producing substrates of TR . TR and GR
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Figure 13. Proposed reaction mechanisms for the modification of protein thiol (RSH), e.g. Cys52 in T. cruzi trypanothione reductase by an
unsaturated Mannic base such as 30 (Modified from Lee et al. 2005).
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Figure 14. Structures and activity of subversive substrates of trypanothione reductase.

nitro-group containing compounds. The results
indicated that the nitrofurans, e.g. nifurtimox act
as futile-cyclers as discussed above, whereas
5-nitroimidazoles, e.g. megazole (32) act as thiol
scavengers particularly for T[SH]2 thus reducing
the thiol/disulfide titer which is detrimental for the
parasites’ survival (Maya et al. 2003). Vega-Teijido
et al (2006) explored three possible binding sites
of TR and GR, i.e. the active site, the dimer interface and the NADPH binding site to study the
mechanism of action of nitrofuran and nitrothiophene analogs. It has been suggested that this class
of compounds act as either uncompetitive or mixed
inhibitors of TR. Moreover, it has also been indicated that the presence of an α-helix connecting
the active site of TR with the interface may be
crucial for charge-transfer processes.
1,4-naphthaqiuinone derivatives (e.g. 33) are
examples of quinine-based subversive substrates
of TR, designed after plumbagin. Compound 33
proved to be a potent subversive substrate and
an effective uncompetitive inhibitor of TR
versus T[SH]2 and NADPH (Salmon-Chemin et
al. 2001).
Most of these compounds were potent inhibitors
of the parasites in vitro. For a series of
naphthaquinones, a correlation between their
potency as subversive substrates in vitro and
trypanocidal activity in vivo has been demonstrated
(Salmon-Chemin et al. 2001). This ‘alternative
approach to chemotherapy of Chagas disease’ has
been considered one of the most promising
advances.

Chemotherapeutic Prospects
of the Trypanothione Reductase
Inhibitors

For an enzyme inhibitor to become a practical
drug, several criteria must be met: (i) the
biochemical pathway that is inhibited must be
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related to the disease state in such a way that
inhibition of that pathway in a patient is therapeutic; (ii) the enzyme inhibitor must be specific
so that unwanted inhibition of other pathways or
receptors does not occur at therapeutic doses;
(iii) the compounds must have the pharmacokinetic characteristics of a practical drug, i.e. must
be absorbed, must penetrate to the site of action
and must have a reasonably predictable doseresponse relationship and duration of action; (iv)
the compound must have an acceptable toxicological profi le in animals, and the results of
clinical studies in humans must demonstrate an
appropriate balance between benefits and risks
in therapeutic use; (v) the compound must survive
a long and expensive clinical development
process and ultimately be approved by regulatory
agencies; (vi) the compound must be economically viable in the marketplace and compete
successfully with other therapeutic alternatives
(Crout, 1989). The criteria (i) and (ii) have
already been addressed while selecting the target,
and thus, all of the above mentioned inhibitors
have fulfilled them. Pharmacological and toxicological studies in animal models are needed to
meet other criteria.
Although many potent inhibitors of TR have
been discovered through enzyme screening, in
vivo evaluation of these lead compounds are scant.
Several polyamine derivatives that were shown
to be potent trypanocidals in vitro (with ED50
values in submicromolar ranges) failed to prolong
the lives of experimental mice infected with
trypanosomes or to cause a significant decrease
in bloodstream parasitemia of infected mice
(O’Sullivan et al. 1997). However, none of the
compounds exerted overt toxicity in mice. It has
been suggested that the lack of in vivo trypanocidal activity may be due to their rapid elimination
and/or metabolism. Since these compounds are
reversible inhibitors of TR, concentrations of
Drug Target Insights 2007: 2
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these compounds may not be maintained, and as
a result, TR activity will not be significantly
decreased (O’Sullivan et al. 1997). It has also
been suggested that converting reversible inhibitors into irreversible inhibitors through complexation with metal ions might be a reasonable
strategy for identifying improved leads with
enhanced in vivo profiles. Clomipramine and
thioridazine were shown to be effective in treatment of mice with experimental Chagas disease
(Rivarola et al. 2001, 2002). The investigation of
effects of clomipramine on T. cruzi infected mice
demonstrated that clomipramine at 5 mg/kg daily
doses for 30 days, or two doses of clomipramine
40 mg/kg given intraperitoneally at 1h and 7 days
after infection, was not toxic for the host, but was
effective against the parasite. Parasitamiasis
became negative and only mild heart structural
and elecctrocardiographic alterations were
detected in chronic phase in the group treated with
clomipramine 5 mg/kg. In mice treated with 40
mg/kg, none of these alterations was detected
(Rivarola et al. 2001). Overall, it has been shown
that clomipramine and thioridazine significantly
modified the natural evolution of the infection.
Cardiac function and survival of infected and
treated animals were not different from noninfected animals. Thioridazine or clomipramine are
currently registered as drugs (antipsychotics) and
meet all the above mentioned criteria. However,
to consider them as antitrypanosomal drugs, dose
becomes an important obstacle, since they need
to be active at a dose which is known to be tolerated by psychiatric patients without causing
adverse events. Apart from their potent in vitro
activity and a preliminary report of in vivo
activity, more detail studies are needed to establish their efficacy and safety and also to improve
their antiparasitic potency. Overall, it would not
be overenthusiastic to consider phenothiazines
and related tricyclic antidepressants and the other
inhibitors of TR as important drug leads for development of future chemotherapy against trypanosomal and leishmanial infections.

Conclusion

The demand for chemotherapeutic agents for the
treatment of Chagas disease, sleeping sickness and
kala azar is desperate. An account of the different
possible targets for rational drug design with
special emphasis on trypanothione reductase has
Drug Target Insights 2007: 2

been focused. TR has been established as a potential target in several studies although it is not
universally accepted. The literature, molecular
graphics and other medicinal chemistry approaches
have led to the development of a large class of
compounds as inhibitors of TR and the parasites.
Considerable progress have been made in terms of
identification, validation and inhibitor design based
on trypanothione reductase as a target, which will
be milestones towards the goal of developing
chemotherapy against these devastating diseases.
This review has revealed several approaches based
on TR towards the development of new drugs
against the parasitic diseases. Reasonable activity
against parasites living in both culture and in
mouse macrophases has been demonstrated by
most classes of compounds, full activity against
whole animal model to be achieved. It has been
suggested that the alternative approaches like
subversive substrates and metal bound inhibitors
would be advantageous in achieving reasonable in
vivo activity against the parasite infection. Only
the phenothiazines and related tricyclic antidepressants were shown to reduce parasite burden in
infected mice. Development of the quaternary
alkylammonium chlorpromazines and congeners,
with an additional hydrophobic moiety provided,
on an average, up to about 30-fold more potent
inhibitors of TR. The charge on N+ is needed for
interaction at the Glu466’ or Glu467’ of the enzyme
active site, the tricyclic or equivalent moiety
interacts with the major hydrophobic cleft and the
second hydrophobic moiety may interact with
Z-site. Studies with other classes of inhibitors, in
addition to the TR:inhibitor complex’s X-ray
crystal structure, provided similar TR:inhibitor
interactive motifs. As with any rational drug design
case at the current stage of computational
development, the problem of bioavailability,
pharmacokinetic, metabolism and targeting have
not been addressed. The prodrug approach might
be a reasonable step in correcting some of the
aforementioned problems in developing TR
inhibitors with observable effects in vivo and might
open a new path towards the development of drugs
against these parasitic diseases.
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